News Releases

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
11/19/2019
4:05 PM ET
Press Release

Diffusion Pharmaceuticals Presents Early Findings Showing Increased Survival in Lead-in Portion of Phase 3 Glioblastoma Study with TSC plus Standard of Care

11/19/2019

CHARLOTTESVILLE, Va., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical con...

 Continue Reading
11/13/2019
9:34 AM ET
Press Release

Diffusion Pharmaceuticals Announces $4.0 Million Public Offering

11/13/2019

CHARLOTTESVILLE, Va., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or the “Company”), a clinical-stage biotechnology company developing new treatments...

 Continue Reading
11/11/2019
8:00 AM ET
Press Release

Diffusion Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

11/11/2019

Commenced Patient Enrollment in Phase 2 On-Ambulance TSC Clinical Trial for the Treatment of Stroke

Reported Favorable Safety Data in Glioblastoma Multiforme Phase 3 Run-in Study
 Continue Reading

10/17/2019
8:30 AM ET
Press Release

First Patient Enrolled in Diffusion Pharmaceuticals’ Phase 2 On-Ambulance Clinical Trial with TSC for the Treatment of Stroke

10/17/2019

CHARLOTTESVILLE, Va., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical con...

 Continue Reading
9/3/2019
10:30 AM ET
Press Release

Diffusion Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference

9/3/2019

CHARLOTTESVILLE, Va., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical co...

 Continue Reading
8/8/2019
5:15 PM ET
Earnings Release

Diffusion Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update

8/8/2019

Company Completes $6.28 Million Registered Direct OfferingFavorable Data Reported in Glioblastoma Multiforme Phase 3 Run-in StudyPhase 2 On-Ambulance TSC Clinical Trial for the Treatment of Stroke Rea...

 Continue Reading
7/23/2019
8:30 AM ET
Press Release

Diffusion Pharmaceuticals Reports Favorable Safety Data for Dose-Escalation Run-in of Phase 3 INTACT Study in Glioblastoma Multiforme Patients

7/23/2019

CHARLOTTESVILLE, Va., July 23, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical con...

 Continue Reading
Displaying 1 to 7 (of 120 releases)